# A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis

> **NCT05359406** · PHASE2 · UNKNOWN · sponsor: **LI XIN-XIANG** · enrollment: 51 (estimated)

## Conditions studied

- Advanced Rectal Cancer
- Distal Metastasis

## Interventions

- **COMBINATION_PRODUCT:** a combination therapy including tislelizumab

## Key facts

- **NCT ID:** NCT05359406
- **Lead sponsor:** LI XIN-XIANG
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2022-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359406, "A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05359406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*